Chronic kidney disease by Romagnani, Paola et al.
22 October 2021
Chronic kidney disease / Romagnani, Paola; Remuzzi, Giuseppe; Glassock, Richard; Levin, Adeera; Jager, Kitty J.;
Tonelli, Marcello; Massy, Ziad; Wanner, Christoph; Anders, Hans-Joachim*. - In: NATURE REVIEWS. DISEASE







(Article begins on next page)
La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla
Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf)
Availability:
This version is available at: 2158/1120344 since: 2021-03-29T21:41:55Z
Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:
FLORE












1 Chronic kidney disease 
 
2 Paola Romagnani1, Giuseppe Remuzzi2, Richard Glassock3, Adeera Levin4, Kitty J. Jager5, Marcello 
 
3 Tonelli6, Ziad Massy7, Christoph Wanner8 and Hans-Joachim Anders9 
 
4 1 Nephrology and Dialysis Unit, Meyer Children's University Hospital, Florence, Italy, 
5 p.romagnani@dfc.unifi.it, 
6 2 IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy, Department of Medicine, 
7 Unit of Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, 
8 Italy, Department of Biomedical and Clinical Science, L. Sacco, University of Milan, Milan, Italy 
9 gremuzzi@marionegri.it 
10 3 Department of Medicine, David Geffen School of Medicine at UCLA, 8 Bethany, Laguna Niguel, 
11 92677 California, USA, rjglassock@gmail.com 
12 4 Division of Nephrology, University of British Columbia, Vancouver, Canada, 
13 alevin@providencehealth.bc.ca 
14 5 ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, Amsterdam, The 
15 Netherlands, k.j.jager@amc.uva.nl 
16 6 Cumming School of Medicine, Division of Nephrology, University of Calgary, Calgary, Alberta, 
17 Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, 
18 Canada, cello@ucalgary.ca 
19 7 Division of Nephrology, Ambroise Paré University Hospital, APHP, University of Versailles-Saint- 
20 Quentin-en-Yvelines, Boulogne-Billancourt, and Inserm U1018 Team5, CESP, Villejuif, France, 
21 ziad.massy@aphp.fr 
22 8 Department of Medicine, Division of Nephrology, University Hospital of Würzburg, Würzburg, 
23 Germany, Wanner_C@ukw.de 
24 9 Medizinische Klinik and Poliklinik IV, Klinikum der LMU München – Innenstadt, Ziemssenstr. 1, 
25 80336 München, Germany 
26 
27 Correspondence to: H.-J.A. 
28 hjanders@med.uni-muenchen.de 
29 
30 Competing interests 
31 PR, GR, AL, KJJ, MT, CW, and HJA declare no competing financial interest. 
32 RG declares competing financial interest as follows: Speaker honoraria from Genentech; Consultancy 
33 honoraria from Bristol Myers Squibb (Abatacept for Lupus or FSGS, Chemocentryx (Avacopan for 
34 vasculitis), Retrophin (Sparsentan for FSGS); Compensated Editorial Tasks - Wolters-Kluwer 
35 (UpToDate, Editor), Karger (American Journal of Nephrology), American Society of Nephrology 
36 (NephSAP, Editor); Stock Ownership- Reata. 
37 ZM declares competing financial interest as follows: Grants for CKD REIN and other research projects 
38 from Amgen, Baxter, Fresenius Medical Care, GlaxoSmithKline, Merck Sharp and Dohme-Chibret, 
39 Sanofi-Genzyme, Lilly, Otsuka and the French government, as well as personal fees, and grants to 















48 Chronic kidney disease (CKD) is defined by persistent urinary abnormalities or impaired excretory 
 
49 renal function. While progression to end stage kidney disease (ESKD) is a concern, the majority of 
 
50 those with CKD are at risk for accelerated cardiovascular disease and death. For those that do reach 
 
51 ESKD  the  limited  accessibility  to  kidney  replacement  therapy  is  a  problem  in  many  locations 
 
52 worldwide.. Risk factors for CKD include low nephron number at birth and nephron loss due to 
 
53 increasing age or acute and chronic kidney injuries. For example, the pandemic of obesity and type 2 
 
54 diabetes  largely  accounts  for  the  increasing  global  prevalence  of CKD  and  there  is  an increasing 
 
55 awareness of genetic causes for CKD and accelerated CKD progression. The management of CKD is 
 
56 focused on early detection or prevention, treatment of the root cause if possible, and attention to 
 
57 secondary processes which contribute to ongoing nephron loss, i.e. remnant nephron hyperfiltration. 
 
58 Blood  pressure  control  and  inhibition  of  the  renin-angiotensin  system  are  the  corner  stones  of 
 
59 therapy.  CKD  complications  such  as  CKD  complications  such  as  anemia,  metabolic  acidosis,  and 
 
60 secondary hyperparathyroidism impact cardiovascular health, as well as quality of life, and so require 
 
61 diagnosis and therapy. Primary prevention of CKD, early diagnosis, and secondary prevention of CKD 
 
62 progression are needed to reduce cardiovascular disease, CKD-related morbidity, and to prevent 
 




65 [H1] Introduction 
 
66 Chronic kidney disease (CKD) is a syndrome defined as persistent alterations in kidney 
 
67 structure,  function  or  both  with  implications  for  health  1.  Examples  of  structural  abnormalities 
 
68 include  cysts,  tumors,  malformations  or  atrophy, which  become  evident  by  imaging.  By contrast, 
 
69 kidney  dysfunction  can  become  evident  as  hypertension,  edema,  growth  delay  in  children,  and 
 
70 changes in output or quality of urine; these changes are most often recognized by increased serum 
 
71 levels of creatinine, cystatin C or blood urea nitrogen. The most common  pathological manifestation, 
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72 regardless of the initiating insult or disease, of CKD is some form of renal fibrosis. 
 
73 The Kidney  Disease Improving Global Outcomes (KDIGO)  initiative classifies  an  individual as  having 
 
74 CKD  if  abnormalities  of  kidney  structure  or  function  persist  for  >3  months.  KDIGO    describes a 
 
75 classification  system based on severity, into  numerous stages of CKD using a two dimensional matrix 
 
76 based  on  estimated  or  measured  glomerular  filtration  rate  (eGFR,  mGFR) and on extent of 
 
77 albuminuria  (FIG. 1) 1. Primary care  settings often do not assess albuminuria  but  proteinuria via  dip 
 
78 stick analysis, but dip stick +, ++, and +++ usually approximates with the three albuminuria stages. 
 
79 GFR and albuminuria/proteinuria are used to classify CKD because GFR is a well-established marker 
 
80 of  renal  excretory  function  and  albuminuria  is  an  indicator  of  renal  barrier  dysfunction,  i.e. 
 
81 glomerular injury. Both have found to be reliable predictors of long term CKD outcomes 
 
82 As the kidney is formed by many independent functional and anatomical ‘units’, the nephrons GFR, 
 
83 can be expressed by the equation: GFR(Total) = GFR(single nephron) × number of nephrons. This implies that 
 
84 when  the  number  of nephrons declines, total GFR  will not  change  as  long  as single  nephrons can 
 
85 increase their individual GFR (known as single-nephron GFR (SNGFR). Vice versa, a decline in total 
 
86 GFR  implies  a  significant  loss  of  nephrons  with  remnant  nephrons  probably  operating  at  their 
 
87 maximum possible SNGFR. That is, CKD can be thought of generally as a loss of functional nephrons 
 
88 but usually represents loss in nephron number. Furthermore, the KDIGO stages are derived from 
 
89 large  databases  of  general,  high  risk  and  nephrology  populations.  The  categories  define  risk  of 
 
90 progression  to  ESKD  that  is  defined  as  G5  (GFR  <15  mL/min/1.73  m2)  and  a  number  of  other 
 
91 outcomes including risk of cardiovascular disease (CVD), death, AKI, infections, and hospitalizations. 
 




94 Whether CKD should be diagnosed and staged using absolute thresholds irrespective 
 
95 of age remains controversial 2, 3. The mGFR in healthy adults aged 20-40 years is about 107 
 
96 ml/min/1.73 m2 and declines at a rate of about 0.7 ml/min/1.73 m2 per year 4, 5. By age 75 
 
97 years, many otherwise healthy individuals (without significant co-morbidity) will have lost 
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98 50% of their nephrons   and their GFR that was present at age 25 years 6. A substantial 
 
99 number  of  older  healthy  individuals  have  eGFR  <60  ml/min/1.73  m2  and  no  abnormal 
 
100 albuminuria (KDIGO CKD G3a A1) meeting the KDIGO criteria for CKD albeit having only a 
 
101 small increase in relative risk of all-cause mortality 7, 8. The threshold of GFR that should be 
 
102 used to detect CKD in younger persons is equally controversial 9. The upper and lower limits for 
 
103 mGFR in a 25 year old healthy person being considered as a living kidney donor is about 136 to 78 
 
104 ml/min/1.73 m2 respectively 5; some have suggested that a threshold of <75 ml/min/1.73 m2 would 
 
105 be more appropriate for young adults, and values below this threshold are associated with a 
 
106 significantly increased relative risk of all-cause mortality and ESKD 10. 
 
107 The etiology of the impaired kidney function is important, and thus in addition to classifying the 
 
108 severity of CKD by GFR and albumin levels, understanding the risk factors or causes of CKD is 
 
109 essential (Box 1), and recommended by the guidelines 1. In this Primer, we discuss the global 
 
110 prevalence of CKD, the different diseases underlying poor nephron endowment or nephron loss, the 
 
111 pathophysiology of CKD progression, the diagnosis, screening, and prevention of CKD, and CKD 
 





potentially offering improvements for CKD management in the near future. 
 
115 [H1] Epidemiology 
 
116 Rates of age-standardized death and disability due to most non-communicable diseases have 
 
117 decreased over the past 20 years, but such favourable trends are not present for CKD. The Global 
 
118 Burden of Disease study reports indicate an increase burden of CKD (with substantial worldwide 
 
119 variation) to which diabetes mellitus seems to be the most important contributor 11-13. CKD as a cause 
 
120 of mortality has increases over the last 25 years from 21st to 13th’, and now contributes 1.35% of the 
 
121 global burden of disability life years lost, growing at a rate of 1% per annum 11, 13, 14. Note that most 
 
122 prevalence data are based on levels of GFR only, without consideration of albuminuria, based on the 
 




































140 younger people with CKD, albeit sometimes over long period of times 26. Interestingly,while the 
 
141 prevalence of CKD is higher in women than in men, men are more likely to progress to ESKD 26. The 
 
142 most common underlying diseases are diabetes mellitus and hypertension, particularly in in high and 
 
143 middle income countries. In those with diabetes, CKD prevalence is estimated in 30- 40%. Whether 
 
144 this is due to diabetes per se or due to microvascular disease is not known.  However, in LMICs, CKD 
 
145 is  often  due  to  infectious  diseases  and  glomerulonephritis  (a  group  of  diseases  that  lead  to 
 
146 inflammation of the glomerulus) 27. Current and future changes in socio-economic circumstances and 
 
147 population age distributions will increase the absolute number of people with CKD in these countries, 
 
148 where numbers of elderly persons are rising, and with increasing diabetes and obesity epidemic, may 
 
149 change the cause of CKD in those populations as well. Furthermore, low birth weight is associated 
124  
125 [H2] Prevalence 
126 CKD stage G3–5 prevalence in adults varies worldwide, with values reported as 1.7% in China 
127 15, 3.1% in Canada 16, 5.8% in Australia 17 and 6.7% in the USA 18. In Europe the range is slightly 
128 narrower: from 2.3% in Germany 19, 2.4% in Finland 20, 4.0% in Spain 20 to 5.2% in England 21. Such 
129 numbers should be viewed with caution because they are often based on a single eGFR assessment 
130 (that is not considering the actual definition, which includes the factor of time (present for >3 mo; 
131 thus it is possible that positive “CKD cases” may overestimate the true prevalence of CKD 22. The 
132 epidemiology of CKD in low and middle-income countries (LMICs) is poorly characterized due to the 
133 lack of community-based studies, inconsistent assessment of kidney function and non-standardized 
134 or non-calibrated approaches23. Nevertheless, in South-East Asia, some Latin American countries 
135 (such as Mexico) and in sub-Saharan Africa, when assessed, the prevalence of CKD appears to be 




[H2] Risk factors 




150 with CKD later in life; the global risks of preterm birth and low birth weight are around 10% and 15%, 
 
151 respectively. Thus, millions of children are born at risk of CKD later in life and are found at the lower 
 
152 percentile of age-matched GFR 28, 29. Specific populations are at higher risk for CKD, in part due to 
 
153 genetic factors, and others due to interaction of genetic and environmental factors. Those groups at 
 
154 higher  risk  include,  in  alphabetical  order:  Aboriginal  Australians,  African  Americans,  Hispanics, 
 
155 indigenous populations in Canada, South Asians, Oriental Asians, and Pacific Islanders. 
 
156 Endemic forms of CKD suggest regional triggers, which are often difficult to define among 
 
157 potential  candidates  such  as  specific  infections,  toxins,  behaviours  or  climate-related  factors  30. 
 
158 Reports of chronic interstitial nephritis or CKD of undetermined origin (CKDu) in sugar cane and other 
 
159 agricultural workers  in Latin America, Sri Lanka, India, and more recently in Cameroon, Mexico, and 
 




162 [H2] Children 
 
163 Little is known about CKD in children because of the absence of registries, and that they are not 
 
164 included in many clinical studies. In Europe, the 2014 incidence of paediatric ESKD was 5.7 per million 
 
165 age-related population (pmarp) in children aged 0-14 years and the prevalence 32.2 pmarp 33. Earlier 
 
166 estimates suggested the incidence and prevalence were 8.3 pmarp and 58 pmarp, respectively, in 
 
167 children aged 0-19 years 34, which is lower than 14.7 pmarp and 103.9 pmarp for the age group 0-21 
 
168 years in the United States 35. In high income countries, congenital disorders are responsible for the 
 
169 majority of cases of paediatric CKD; by contrast, in acquired causes, such as infection and glomerular 
 




172 [H2] Kidney replacement 
 
173 Understanding the information on kidney replacement therapy in the context of CKD is important for 
 
174 identifying gaps and focusing on solutions to those gaps 37. Often countries do not know the number 
 
175 of patients with prevalent CKD but do have information on dialysis numbers. Given that not all 
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176 people progress to ESKD, estimates of those with CKD can be extrapolated; conversely if CKD rates 
 
177 are known then numbers on dialysis can reveal inequities in availability of dialysis. Data on the 
 
178 incidence of kidney replacement therapy for ESKD can only be obtained from countries with dialysis 
 
179 registries. Data are missing in particular from LMICs, where such registries do not exist. In 2014, 
 
180 incidence of kidney replacement therapy varied from 49 per million population (pmp) in Bangladesh 
 
181 to as high as 455 pmp in Taiwan 38. The majority of patients started kidney replacement therapy on 
 
182 dialysis, because pre-emptive transplantation as an initial modality is not freely available. Kidney 
 
183 transplant rates differed substantially by country from 1 pmp in Bangladesh to 60 pmp in Jalisco 
 
184 (Mexico). There was also huge variation in the prevalence of kidney replacement therapy (FIG. 2): 
 
185 from 113 pmp in Bangladesh to 3,219 pmp in Taiwan 38. 
 
186 In many European countries, more than half of all kidney replacement therapy patients are 
 
187 transplant recipients 38. This is in contrast to the situation in some Asian countries like Taiwan, Japan 
 
188 and the Philippines where kidney transplantation is hardly performed 38. There are multiple reasons 
 
189 why transplantation is not available despite the availability of expensive dialysis services: cultural, 
 
190 socioeconomic and health care infrastructure deficiencies (lack of biopsy services, lack of surgeons, 
 
191 lack  of  immunology  laboratories)  account  for  many  of  these.  Existence  of  available  dialysis and 
 
192 transplant services has not been systematically documented; however the Global Kidney Health Atlas 
 
193 [38; full report at www.theisn.org] describes availability of kidney replacement therapy worldwide. 
 
194 Note that the registry data for dialysis and transplantation described above does not reflect the true 
 
195 need for kidney replacement therapy, which may account for the wide variability in incidence and 
 
196 prevalence.  Estimates  of  unmet  need  vary  from  2  to  7  million  people  per  year  39.  Note  that 
 
197 availability and accessibility are not the same, and even when services ae available in a country or 
 













204 [H2] Nephron loss and compensation 
205 In humans, nephrons are generated from the 12th-36th week of gestation with a mean 
206 number of 950,000 per kidney in a range from approximately 200,000 to >2.5 million 40. No new 
207 nephrons can form upon injury and, during growth from childhood to adulthood, the available 
208 nephrons increase in size to accommodate increased renal demands. However, as people age, GFR 
209 declines (FIG. 3). Although nephrons can deal with transient increases in filtration load (such as upon 
210 food and fluid intake) by transient increases in SNGFR (“renal reserve”) 41, 42, longer or persistent 
211 increases in body mass (for example, during pregnancy or obesity) promote nephron hypertrophy as 
212 the compensatory mechanism. Any injury- (or kidney donation-)related nephron loss may have the 
213 same effect (FIG. 4). Indeed, either severe kidney injury or combinations of injury with ageing-related 
214 nephron losses — especially in individuals with poor nephron endowment and/or obesity — 
215 accelerates persistent increased SNGFR and loss of remnant nephrons43. 
216 Remnant nephron hypertrophy is triggered by persistent elevations of SNGFR and filtration 
217 pressure (that is, glomerular hypertension) across the glomerular filtration barrier, which implies 
218 glomerular hyperfiltration. Specifically, glomerular hyperfiltration and hypertension together 
219 promote the release of tumour growth factor-alpha/epithelial growth factor receptor 44, 45, leading to 
 
220 nephron  hypertrophy  that  reduces  glomerular  hypertension  by  increasing  filtration  surface  46. 
 
221 Indeed, increased SNGFR and remnant nephron hypertrophy allows kidney donors to maintain an 
 
222 apparently  “normal”  renal  function,  despite  lacking 50%  of nephrons.  Obviously,  kidney donation 
 
223 does not necessarily cause CKD progression when donors are carefully selected for good nephron 
 
224 endowment, the absence of obesity, diabetes, and ongoing nephron injury 47, 48. However, in other 
 
225 circumstances, hyperfiltration-driven  increases in  glomerular  dimensions can potentially be harmful 
 
226 42, 46, 49-51. Beyond a certain threshold of hypertrophy, increasing podocyte (which are key octopus- 
 
227 shaped cells that maintain the glomerular filtration barrier of the nephron shear stress promotes 
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228 podocyte detachment, focal segmental glomerulosclerosis (FSGS, a pathological entity in which  renal 
 
229 injury results in sclerotic lesions in segments of glomeruli), global glomerulosclerosis and subsequent 
 
230 nephron  atrophy,  a  vicious  cycle  further  reducing  nephron  number  and  the  SNGFR  of  remnant 
 




233 [H2] Impaired glomerular filtration and fibrosis 
 
234 Persistent podocyte hypertrophy and glomerular hyperfiltration, maintained by angiotensin II 
 
235 production, ultimately aggravate podocyte loss and proteinuria, eventually impacting on glomerular 
 
236 filtration  Angiotensin-II,  a peptide hormone that  is part  of the renin-angiotensin  system  (RAS)  and 
 
237 drives vasoconstriction  and  aldosterone  secretion  (and  thus  sodium  retention  and  an increase of 
 
238 blood  pressure)  directly  impairs  the  glomerular  barrier  sieving  function,  possibly  via  inhibiting 
 
239 expression of the podocyte protein nephrin, a structural component of the slit diaphragm necessary 
 
240 for  maintaining  the  glomerular  filtration  barrierindependently  of  its  hemodynamic  effects  56. 
 
241 Angiotensin-II  possibly   also   contributes  to   the  dysregulated   response  of  parietal  epithelial cell 
 
242 precursors along Bowman`s capsule, generating FSGS lesions instead of replacing lost podocytes 57. 
 
243 This   structural   remodelling   of   the   glomerular   tuft   barrier   presents   clinically   as proteinuria. 
 
244 Proteinuria not only serves as a marker for nephron damage but also predicts CKD progression 44, 58, 
 
245 59. Mechanistically, albuminuria also impairs the capacity of parietal epithelial cells to regenerate 
 




248 CKD progression also involves non-specific wound healing responses including interstitial fibrosis. 
 
249 Albuminuria and complement, and infiltrating immune cells activate proximal tubular epithelial cells 
 
250 to  induce  the  secretion  of  and  pro-fibrotic  mediators  followed  by  interstitial  inflammation   and 
 
251 fibrosis 62. Interstitial fibrosis is frequently considered as an additional factor driving further nephron 
 
252 injury, e.g. via promoting renal ischemia 62 but, as in other organs, scar formation may also be 
 
253 essential  to  mechanically  stabilize  the  remaining  nephrons  63.  The  increased  tubular  transport 
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254 workload of remnant nephrons also involves anaerobic metabolism, intracellular acidosis, and 
 




257 [H2]Risk factors 
 
258 Several factors can contribute to the pathogenesis of CKD, including low birth weight, pregnancy, 
 
259 obesity,  diabetes,  and  ageing.  Each  of  these  scenarios  contributes  different  factors  that  lead to 
 







263 [H3]Prematurity and low birth weight. 
 
264 Newborns  with  low  birth  weight  (owing  to  preterm  birth  or  intrauterine  growth  restriction) 
 
265 frequently display incomplete kidney development 64-66. Depending on the severity of prematurity, 
 
266 poor  nephron  endowment  can  cause  either  early  childhood  CKD  or  CKD  later  in  life  64-70.  The 
 
267 associated  risk  was  estimated  among  US  adolescents  for  every  13  individuals  born  at  low birth 
 
268 weight, one had reduced GFR and one had raised systolic blood pressure, and this risk increases with 
 
269 age 29. The risk of low birth weight infants (<2599 g) to experience CKD up to the age of 17 is fourfold 
 
270 increased compared to infants with a birth weight of >2500 g (FIG.3B) 69. CKD onset at puberty is 
 
271 common in  these  individuals when rapid  body growth  exceeds the capacity  of nephron  number to 
 
272 accommodate the increasing filtration load71. In milder cases, poor nephron endowment at birth 
 
273 promotes  the  development  of  hypertension,  CKD  later  in  adults  or  a  faster  progression  of 
 








278 Congenital  abnormalities  of  the  kidney  and   the   urinary  tract  (CAKUT)   are  the   most   common 
 
279 congenital abnormalities  74. CAKUT  present  a wide  spectrum  of  causes  for   kidney  hypodysplasia, 
274 glomerulonephritis to ESKD (FIG.3C) 
275 cardiovascular disease. 
276 
 




280 imparting low nephron number and risk of CKD later in life75, 76. Genetic testing has revealed that 
 
281 ~20% of early-onset CKD (defined as CKD manifesting before 25 years of age) cases can be attributed 
 
282 to a monogenic cause 77. Beyond CAKUT, these conditions include ciliopathies, cystic kidney diseases, 
 
283 tubulopathies, and podocytopathies causing FSGS 75-78. 
 
284 Until recently, monogenic causes of CKD were mostly reported in children or adolescents, but 
 
285 genetic variants also contribute as co-factors to CKD progression in adults (FIG. 4). For example, an 
 
286 UMOD gene variant, present on 17% of the alleles in the general population, is associated with CKD 
 
287 79-81. Another example is gene variants of apolipoprotein L1 (APOL1) in African Americans, which 
 
288 confer resistance to Trypanosoma brucei infections in sub-Saharan Africa 82. However, these variants 
 
289 affect   endosomal   trafficking   and   autophagic   flux,   which   ultimately   leads   to   podocyte  loss, 
 
290 glomerulosclerosis, nephron loss, and CKD progression 83, 84. This may explain faster CKD progression 
 






294 A larger glomerular size on mildly obese (BMI>30 and <35) but otherwise healthy individuals suggests 
 
295 an  increased  SNGFR  85.  In  general,  the  association  between  obesity  and  poorer  renal outcomes 
 
296 persists even  after  adjustments  for higher  blood  pressure  and  diabetes  mellitus, suggesting   that 
 
297 obesity-driven glomerular hyperfiltration directly contributes to nephron loss 86, 87. Severe obesity 
 
298 alone or moderate obesity in combination with other factors such as genetic, low nephron number 
 






302 The latter trimester of pregnancy involves volume expansion (that is, an increase in blood volume) 
 
303 causing  an  increase  of  total  GFR  by  50%  92,  implying  a  respective  increase  of  SNGFR.  These 
 
304 physiological adaptations are transient and without consequences in women with normal nephron 
 
305 number. However, in women with low nephron endowment or previous injury-related CKD (such as 
13  
 
306 in women with lupus nephritis), pregnancy-related glomerular hyperfiltration exacerbates remnant 
 
307 nephron glomerular hyperfiltration and hypertrophy. In some patients, final trimester pregnancy- 
 
308 related glomerular hyperfiltration then passes the threshold of compensation and triggers rapid CKD 
 
309 progression presenting with proteinuria and hypertension — a condition known as eclampsia. Pre- 
 
310 existing CKD G3A2 or higher, obesity, excessive body weight increase during pregnancy are well- 
 






314 Diabetes is a well-known condition associated with massive glomerular hyperfiltration, evident from 
 
315 increased  total  GFR  and  renomegaly  51.  Hyperglycemia  promotes  the  sodium-glucose transporter 
 
316 (SGLT)-2-driven  reabsorption  of  sodium  in  the  proximal  tubule,  a  process  that  subsequently 
 
317 inactivates tubuloglomerular feedback and activates the RAS at the macula densa 94, 95. The result is 
 
318 induction  of  a  permanent  dilation  of  the  afferent  arteriole  and  vasoconstriction  of  the efferent 
 
319 arteriole — permanently increasing SNGFR and total GFR 96. 
 
320 Although diabetes-driven glomerular hyperfiltration can be compensated for many years in 
 
321 younger patients with normal nephron number, it serves as a drastic accelerator single nephron 
 
322 hyperfiltration such as patients with low nephron endowment, injury- or ageing-related nephron 
 
323 loss, obesity or those who are pregnant 97. Unfortunately, this is a highly prevalent combination of 
 
324 risk factors in older patients with type 2 diabetes, for which dual SGLT2/RAS inhibition can elicit 
 




327 [H3]Acute kidney injury. 
 
328 Acute kidney injury (AKI) is a clinical syndrome defined by an acute deterioration of renal function 
 
329 resulting in the accumulation of metabolic waste and toxins, subsequent uremic complications, and 
 
330 potentially failure of other organs 99. AKI is highly prevalent in hospitalized patients and can imply 
 
331 irreversible losses in nephron number100. In Western countries AKI occurs in both outpatient and 
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332 inpatient settings, the latter of which is simpler to document, and has been the focus of multiple 
 
333 papers  describing  the  phenomenon  and  aiding  in  the  understanding  of  the  strong  association 
 
334 between AKI and CKD. The causes of non hopsital/institutuion-based AKI are diarrhea, infections, 
 
335 dehydration, medications, while in hospital it can be attributed to these same factors and exposures 
 
336 to nephrotoxins (dye) and is mostly observed in patients with multiple morbidities 101.  By contrast, in 
 
337 LMICs and tropical countries, AKI occurs frequently outside the hospital setting following episodes of 
 
338 diarrhoea,  infections  and  obstetric  complications  102.  Nephrotoxins  can  also  cause  AKI-related 
 
339 nephron  loss  inside  and  outside  hospitals;  for  example,  neonates  treated  with aminoglycosides, 
 
340 cancer patients receiving chemotherapy or communities exposed to environmental toxins such as 
 






344 The slope of GFR decline varies among individuals depending upon age (FIG. 3), genetic factors, blood 
 
345 pressure,  diseases  implying kidney injury and  body  weight. Histologically, kidney ageing presents as 
 
346 global  glomerulosclerosis,  the  respective  atrophy  of  entire  nephrons,  and  subsequent interstitial 
 
347 fibrosis  53, 85. Whether  ageing-related  nephron  loss is  associated  with hypertrophy (and glomerular 
 
348 hyperfiltration)  of  remnant  nephrons  is  not  consistently  reported  in  the  literature  53, 85,  but the 
 
349 analytical difficulties on how to precisely assess nephron number, glomerular volume, and how to 
 
350 acknowledge  the  different  functions  of  juxtamedullary  versus  cortical  nephrons  can  affect  the 
 
351 interpretation of such data 53, 85. Ageing is associated with decreasing podocyte density and total 
 
352 numbers 53. Endomitosis-related mitotic catastrophe and podocyte detachment may contribute to 
 




355 [H2]Systemic effects 
 
356 The kidney is involved in multiple complex hormonal processes important in anemia, bone 
 
357 integrity, in regulation of acid base and electrolyte homeostasis, as well as blood pressure control 
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358 through neuroendocrine and volume sensors. As nephron mass declines, patients will suffer from 
 
359 complications associated with dysregulation of many of these systems. Anemia, vitamin D deficiency, 
 
360 hyperparathyroidism,  acidosis,  hyperkalemia  and  hyperphosphatemia,  hyperuricemia,  as  well  as 
 
361 hypertension  and expansion  of  effective  circulating  fluid  volume  are  all clinical  manifestations of 
 
362 these derangements. Interestingly, they do not occur in all individuals at the same point in the 
 
363 progressive  loss  of  kidney  function,  and  there  are  some  maintain  excellent  tubular/  excretory 
 
364 function despite derangements in hormonal function (i.e. severe anemia, and normal electrolytes). 
 
365 Not all of the derangements are symptomatic, and the severity of the symptoms is variable 
 
366 between individuals. They include: disorders of fluid and electrolytes, mineral and bone disorder, 
 
367 anemia,   hypertension,   dyslipidemia,   endocrine   abnormalities,   in   children   growth impairment, 
 
368 decreased clearance of renally excreted substances from the body (eg, hyperuricemia), metabolic 
 
369 acidosis.  Related  symptoms  may  be  fatigue, anorexia, weight loss, pruritis, nausea,  vomiting, 
 




372 [H3] Fluid and electrolyte abnormalities. 
 
373 Sodium and water balance — Sodium and intravascular volume balance are usually maintained via 
 
374 homeostatic  mechanisms  until  the  GFR  falls  below  10  to  15 mL/min per  1.73  m2.  However,  the 
 
375 patient with mild to moderate CKD, despite being in relative volume balance, is less able to respond 
 
376 to rapid infusions of sodium and is, therefore, prone to fluid overload. In some cases, especially with 
 
377 an acute water load, hyponatremia and hypertension may occur as a consequence of fluid retention. 
 
378 Some patients, such as those with nephronophthisis and some with obstructive uropathy, have an 
 
379 impaired ability to concentrate urine, and have symptoms of polyuria. These children are at risk for 
 
380 hypovolemia, as they will continue to have large urine losses even when they are volume depleted. 
 
381 Hyperkalemia — In   children   with   CKD,   hyperkalemia   develops   due   to   reduced   GFR  causing 
 
382 inadequate potassium excretion. Also, potassium excretion is dependent upon an exchange with 
 
383 sodium at the distal tubule. A low GFR decreases delivery of sodium to this site where there is 
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384 reduction in the exchange rate with potassium into the urinary lumen. Other contributory factors for 
 
385 hyperkalemia  include:  high  dietary  potassium  intake,  catabolic  conditions  with  increased  tissue 
 
386 breakdown, metabolic acidosis, secondary type IV renal tubular acidosis (RTA) in some patients with 
 
387 obstructive  uropathy,  decreased  renin  production  by  the  juxtaglomerular  apparatus,  primary  or 
 
388 secondary hypoaldosteronism related to RAS inhibitor-related impaired cellular uptake of potassium 
389 
390 [H3]Metabolic acidosis. 
 
391 Metabolic  acidosis  is  observed  in  patients  with  advanced  CKD  and  is  related  to  the  fall  in total 
 
392 ammonium  excretion  that  occurs  when  the  GFR  decreases  to  below  40  to  50 mL/min  per  1.73 
 
393 m2  (GFR category G3). In addition, there is a reduction in both titratable acid excretion (primarily as 
 
394 phosphate) and bicarbonate  reabsorption. As the patient  approaches ESKD,  the serum  bicarbonate 
 
395 concentration tends to stabilize between 12 and 20 mEq/L. A level <10 mEq/L is unusual, as buffering 
 





concentration. In children with CKD, metabolic acidosis has a negative impact on growth. 
 
399 [H3] Anemia. 
 
400 The anemia of CKD is due primarily to reduced renal erythropoietin production. The anemia of CKD  is 
 
401 principally  normocytic  and  normochromic.  By  comparison,  the finding  of microcytosis may reflect 
 
402 iron deficiency or aluminum excess, while macrocytosis may be associated with vitamin B12 or folate 
 





attentiveness, increased somnolence, and poor exercise tolerance. 
 
406 [H3]Mineral bone disease. 
 
407 Chronic kidney disease-mineral and bone disorder (CKD-MBD) presents as a broad clinical spectrum 
 




409 that are found with progressive CKD. Patients with mild CKD (G2 KDIGO) may have reduced serum 
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410 calcidiol and/or calcitriol levels, and an elevated serum parathyroid hormone (PTH) and fibroblast 
 
411 growth factor 23 (FGF-23) level 105. Patients with more advanced CKD-MBD have bone pain, difficulty 
 






415 Hypertension  can  be  present  in  the  earliest  stages  of  CKD,  and  its  prevalence  increases  with 
 
416 progressive declines in GFR. Hypertension is high in children with CKD, ranging from 54 to  70 percent 
 
417 of patients 107. Hypertension is due to activation of the RAS and volume expansion. In some cases, 
 


















426 Elevated uric acid levels may develop in patients with CKD due to decreased urinary excretion. Serum 
 





should be treated to have a better outcome. 
 
430 [H3]Cardiovascular disease. 
 
431 CVD is the leading cause of death in patients with CKD worldwide 14. The increased incidence of CVD 
 
432 is due to the high prevalence of CVD risk factors, such as hypertension, dyslipidemia, hyperuricemia, 
 
433 abnormal glucose metabolism obesity.  Young  adults (25 to 34 years) with CKD have  at  least  a  100- 
 




435 glomerular etiology  of CKD  and  proteinuria  were  more  likely  to  have  CVD  risk  factors.  The CKD- 
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436 related cardiovascular alterations resemble all aspects of an accelerated ageing process associated 
 
437 with  a  shortening  of  relative  telomere  length  109.  The  vasculature  can  be  affected  by  both, 
 
438 atherosclerosis and arteriosclerosis, with lipid-rich plaques but also abundant media calcification. The 
 
439 burden  of  atherosclerotic  CVD  increases  in  the  early  stages  of  CKD,  and  the  burden  of  non- 
 
440 atherosclerotic  CVD  increases  in  the  more  advanced  stages  of  CKD.  The  „two“  diseases  involve 
 
441 different factors that cause distinct changes in the risk factor profile and contribute differently to 
 
442 outcomes  during  the  course  of  CKD.  Adaptive  changes  of  the  heart  include  left  ventricular 
 
443 hypertrophy (LVH) but also dilatation with subsequent both, systolic and diastolic dysfunction. There 
 
444 are two different patterns of LVH: concentric LVH, which occurs in the presence of hypertension,  and 
 
445 eccentric LVH, which is associated with volume overload and anemia. Early and sustained induction 
 
446 of fibroblast growth factor-23 was recently discovered as a driver of LVH in CKD 110. 
 
447 The absolute risk of cardiovascular events in individuals with pre-dialysis CKD is similar to 
 
448 that  of  patients  with  established  coronary  artery  disease  in  the  general  population  111,  and the 
 
449 increase  in  risk  multifactorial:  a  higher  prevalence  of  insulin  resistance  112,  high  blood pressure, 
 
450 vascular calcification 113, 114, inflammation and protein-energy wasting 115. ESKD is associated with a 
 
451 range of metabolic abnormalities, the so-called milieu of uremic toxicity 116, activation of the neuro- 
 
452 hormonal  axis  117,  vitamin  D  receptors  113,  that  may  all  contribute  to  accelerated  ageing  of the 
 
453 vasculature and damage to the heart. Hemodialysis itself may have a direct negative effect on the 
 
454 heart, so-called myocardial stunning 118. As a consequence the cardiac and vascular mortality are 
 
455 several times higher in patients with low GFR or on dialysis than in the general population. Thus, the 
 
456 risk of CVD in patients who require dialysis depends largely on their cardiovascular health at dialysis 
 
457 initiation.  In  patients  with  healthy  arteries,  the  pre-dialysis  management  strategy  should  be 
 





managed intensively in the pre-dialysis period, during transition, and at dialysis initiation. 
 
461 [H3]Endocrine dysfunction. 
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462 In  patients  with  CKD,  the  following  endocrine  systems  become  dysfunctional  as  kidney function 
 
463 progressively  deteriorates.  Each  of  these  is  discussed  in  greater  detail  separately.  There  are 
 
464 abnormalities in gonadal hormones in both male and female patients, which can results in reduced 
 
465 fertility and sexual problems. In children, these abnornalities result in delayed puberty in two-thirds 
 
466 of  adolescents  with ESKD  119. End-organ  resistance to  GH  due to increased levels of insulin  growth 
 
467 factor binding proteins appears to play a major role in growth impairment in children with CKD 120. 
 
468 Abnormalities in thyroid function can also be observed. 
 
 
469 [H3]Neurological signs. 
 
 
470 Uremia is associated with cognitive alterations ijn adults and lower performance in all neurocognitive 
 
471 domains  development  in  children.  The  neurologic  findings  can  range  from  seizures  and  severe 
 
472 intellectual disability to subtle deficits. 
 
 
473 [H3]Sleep and fatigue. 
 
 
474 Daytime sleepiness and fatigue are common and increase with decreasing kidney function. Sleep 
 
475 disorders (restless leg syndrome/paroxysmal leg movements, sleep-disordered breathing, excessive 
 






478 The onset of ESKD (ie, GFR category G5) results in a constellation of signs and symptoms 
 
479 referred to as uremia. Manifestations of the uremic state include anorexia, nausea, vomiting, growth 
 
480 retardation,  peripheral neuropathy,  and central  nervous system  abnormalities ranging from loss  of 
 
481 concentration and lethargy to seizures, coma, and death. Patients who are uremic also have an 
 
482 increased tendency to bleed secondary to abnormal platelet adhesion and aggregation properties. 
 










487 [H1] Diagnosis, screening and prevention 
 
488 The  clinical  presentation  of  CKD depends upon  the  underlying  disorder  and  the  severity  of renal 
 
489 impairment.  Patients  with  early  stages  of  CKD  G1-2  are  usually  asymptomatic.  From  CKD  G3-5 
 
490 patients  may  experience  weakness  related  to  anemia  and  polyuria.  Only  in  late  stages  and  in 
 





referred to as symptoms of uremia. 
 
494 [H2]Detection and diagnosis 
 
495 CKD can be detected during a periodic health assessment in an asymptomatic person or during 
 
496 evaluation  of  individuals  at  risk  for  CKD  (Box  1);  as  a  consequence  of  the  incidental  finding  of 
 
497 abnormal laboratory values in connection with an acute or chronic illness; during an investigation of 
 
498 symptoms  and/or  signs  relating  to  the  kidneys  or  urinary  tract  (such  as  haematuria);  or during 
 
499 discovery of abnormal laboratory values in a population-based screening program. Importantly, the 
 
500 two biochemical parameters (GFR and proteinuria) used in the aforementioned KDIGO matrix1 define 
 
501 and classify a “generic” form of CKD, and adding an etiological diagnosis is both highly desirable and 
 
502 recommended  by  KDIGO  (The  Cause/GFR/Albuminuria  [CGA]  classifications  system),  whenever 
 
503 possible,  such  that  the  underlying  conditions  can  be  treated  first  to  halt  progression  of  CKD. 
 
504 Progression is defined according to changes in eGFR by KDIGO1. Several tests can be performed to 
 
505 confirm a CKD diagnosis and identify its cause. It must be stressed that a diagnosis of CKD, according 
 





months. A single value of GFR or albuminuria is insufficient and if used for diagnosis of CKD will lead 
 
509 [H3] Measuring and estimating GFR. 
 
510 First, the assessment begins with measurement of serum creatinine concentration (under steady- 
 
511 state conditions) and applying formulas for estimated GFR (eGFR – creatinine, like CKD-EPI eGFR- 
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512 creatinine). It must be recognized that the results of these creatinine based tests  can be influenced 
 
513 by changes in muscle bulk (atrophy or hypertrophy), dietary intake of cooked red meat (strict vegan 
 
514 diet) and alterations in tubular secretion of creatinine from exposure to drugs (e.g. trimethoprim- 
 
515 sulfamethoxazole) 121, 122. Alternative approaches using serum cystatin_C concentrations have also 
 
516 been proposed.  While not influenced by muscled bulk and diet, the cystatin C -based formulas for 
 
517 eGFR can be affected by inflammation, obesity, thyroid disease, diabetes, and steroid administration 
 
518 123. Second, some eGFR  formulashave not been extensively  validated in older  subjects and  may not 
 
519 apply to Asians or Africans 124, 125. Third, the requirements for inclusion of demographic variables of 
 
520 age  and  gender,  to  correct  for  differences  in  creatinine  generation,  may  also  create  unwanted 
 
521 complications in determining prognostic implications of a calculated GFR . Newer eGFR formulas such 
 
522 as FAS (full age spectrum) or CKD-EPI using serum creatinine, cystatin C or a combination or Cystatin 
 
523 C or a combination of both have improved accuracy to predict mGFR 126, 127. Although cumbersome 
 
524 and expensive, mGFR assessments using urinary clearance methodology can sometimes be needed, 
 
525 but  applying  methods of plasma  clearance  of  Iohexol or of  radiolabelled  Iothalamate  could avoid 
 
526 some  of  these  issues.  In  well-defined  circumstances,  such  as  stratifying  long  term  risks  of  uni- 
 
527 nephrectomy for potential living kidney donors, such studies can be useful 128, 129. As mentioned in 
 
528 the   introduction,   caution   should   be   exercised   in   using   a   fixed   and   arbitrary   threshold  of 
 
529 <60ml/min/1.73m2  of  GFR  alone  (in  the  absence  of  abnormal  proteinuria  or  imaging)  for  the 
 
530 diagnosis  of  CKD  in  older  or  elderly  adults.  A  GFR  of  45-59ml/min/1.73m2  is  fairly  common  in 
 
531 otherwise healthy seniors, depending on their age, due to the normal physiologic loss of nephrons 
 




534 [H3]Measuring proteinuria. 
 
535 Abnormal rates of urinary excretion of albumin or total protein are essential for detection of 
 
536 CKD  when  GFR  is  normal  and  contribute  to  the  assessment  of  prognosis  131.  Proteinuria  (or 
 
537 albuminuria) can be determined in multiple ways, including simple “dip stick” qualitative methods, 
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538 point-of-care urinary albumin concentration tests, random un-timed urine samples for calculation of 
 
539 urine protein (or albumin) to creatinine ratios (UPCR or UACR in mg/mg or mg/mmol), or timed 24 
 
540 hour urine collections and measuring absolute protein or albumin excretion 132, 133. Each of these has 
 
541 advantages and pitfalls.  But it is important to recognise that not all patients with CKD have abnormal 
 
542 urinary protein excretion.  For example, early in the course of Autosomal Dominant Polycystic Kidney 
 
543 Disease the urinary protein exertion is normal only slightly increased 134. 
 
544 Urinary protein or albumin excretion is more variable than serum creatinine levels, and can 
 
545 be influenced by posture, activity, fever or drugs so multiple specimens must be collected to enhance 
 
546 reliability. UPCR and UACR methods can be influenced by the prevailing urinary creatinine excretion 
 
547 rate;  i.e.  low  creatinine  excretion  (from  sarcopenia)  can  increase  UPCR  or  UACR  values  even at 
 
548 normal  absolute  protein  or  albumin  excretion  rates.  Hence,  adjusting  for  the  effect  of  urinary 
 
549 creatinine excretion can enhance the accuracy of UPCR and UACR measurements 132, 133. 
 
550 In the KDIGO schema, UACR values are divided into three categories 1, namely, normal or 
 
551 low,  which  is  <30  mg/g  creatinine  (<3.0  mg/mmol,  formerly  “normo-albuminuria”);  moderately 
 
552 increased, which is ≥30-299 mg/g creatinine  (>3.0-29 mg/mmol, formerly “micro-albuminuria”); and 
 
553 severely  increased, which  is  ≥300 mg/g creatinine  (30  mg/mmol,  formerly   “macro-albuminuria”). 
 
554 Even with a normal eGFR, CKD can be diagnosed with persistent UACR of >30 mg/g creatinine. Each 
 
555 incremental increase in UACR is associated with an increased risk of mortality and ESKD, so sustained 
 
556 albuminuria (or proteinuria) is a powerful prognostic marker. 
 
557 The corresponding “dipstick” (urinalysis test strip) values (and protein concentration in 
 
558 mg/dL) are negative (<10 mg/dL) to trace (10-15 mg/dL) for normal, 1+ (30 mg/dL) for moderate and 
 
559 2+ (>100 mg/dL) or greater for severe proteinuria. Persistent proteinuria of >1+ is a good predictor of 
 
560 a tendency for CKD progression, i.e. GFR decline of > 5 ml/min/1.73 m2/year or 7 times the normal 
 
561 rate  of  loss  with  ageing  135.  Thus,  albuminuria  or  proteinuria  allow  early  detection  of  CKD (see 
 
562 Screening below), but several forms of progressive CKD can present with normal or only slightly 
 
563 increased  albumin  or  protein  excretion,  especially  tubulo-interstitial  diseases  such  as  autosomal 
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564 dominant  polycystic  kidney  disease  134.  Marked  proteinuria  (in  excess  of  3.5  g/d  in  and  adult), 
 
565 especially  when  accompanied  by  a  reduction  in  serum  albumin  concentration  (referred  to  as 
 
566 “nephrotic syndrome”) nearly always implies a diagnosis of a primary or secondary glomerulopathy 
 




569 [H3]Biopsy and pathology. 
 
570 Percutaneous kidney  biopsy  is  a very valuable tool in assessement of the  underlying cause for  CKD. 
 
571 The indications for performance of a renal biopsy in a patient with CKD depends upon the benefits to 
 
572 be obtained (precise diagnosis, better prognosis, appropriate therapy) and the risks of a biopsy- 
 
573 related  complications. Kidney biopsies are commonly recommended for adult patients with 
 
574 nephrotic  syndrome (urine protein excretion of >3.5 g/d and serum albumin levels <3.5 g/dL) but 
 
575 may  also  be  indicated  for  evaluation  of  unexplained  rapidly  progressive  loss  of  kidney function, 
 
576 persistent hematuria and low-grade- proteinuria (0.5-3 g/d), of even isolated proteinuria (1-3 g/d) 137. 
 
577 Depending on the circumstances leading to the procedure,  the pathologic findings can vary widely, 
 
578 but in states of marked proteinuria glomerular diseases are most likely be seen.   The degree of 
 
579 tubule-interstitial  scarring  can  provide  useful prognostic  information. The  risks of renal biopsy  are 
 
580 minimal in experienced hands,  and complications are  mostly related  to  post-biopsy  bleeding. Fatal 
 
581 complications are rare (about 1;20,000). Major complications, such as nephrectomy or transfusion 
 




584 [H3]Other tests. 
 
585 Continuing advances in the field of serum and urine proteomics, microRNA biology and in serology 
 
586 are providing many new powerful and non-invasive tools to identify specific diseases or groups of 
 
587 diseases that may revolutionize the approach to detecting and diagnosing CKD in the future 140. 
 
588 These  new  tools  may  also  expand  the  horizon  of  prognosis  into  new  areas  beyond  GFR  and 
 
589 proteinuria  estimation —  giving rise to exciting  new  possibilities  for  “precision”  medicine whereby 
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590 care of CKD is personalized based diagnostic and prognostic characteristics. Unfortunately, many 
 
591 patients with CKD are only recognized in the later stage of the disease (Categories G3B-G5) where 
 







595 In addition, both detection and diagnosis of CKD, also rely on renal imaging (ultrasonography, CT and 
 
596 MRI),  careful examination  of the urinary  sediment,  and  specialized biochemical and  serologic tests 
 
597 suitable to detect specific disorders causing CKD (Box 2). Imaging tests are particularly valuable as 
 
598 they provide information on kidney size, contours, location, and density as well as anatomy of the 
 
599 urinary  drainage  system  (pelvis,  ureters  and  bladder).  Specific  lesions,  such  as  cysts,  dilation of 
 
600 ureters or pelvis, calcification, masses, scars an provide valuable clues to the cause of CKD or even 
 
601 generate a specific diagnosis (such as autosomal dominant polycystic kidney disease or obstructive 
 
602 uropathy) 141. Then urine sediment examination is important for the detection and quantification of 
 
603 haematuria, leukocyturia and casts. 
 
604 Genetic testing is also emerging as an  important  tool for  diagnosing CKD, particularly  in  children or 
 
605 young  adults.  Autosomal  dominant  polycystic  kidney  disease,  podocytopathies  causing  steroid- 
 
606 resistant  nephrotic  syndrome,  Fabry’s  disease,  Alport  syndrome,  are  other  well-known  entities 
 
607 requiring  a  genetic  diagnosis.  Using  next-generation  sequencing  displays  an  unexpected  genetic 
 
608 heterogeneity and alterations in numerous different genes in a significant proportion of not only 
 
609 familial or syndromic patients but also in sporadic cases of CKD. These observations imply the need 
 







614 In the context of CKD, screening can take two forms: population screening, for example, using 
615 “dipstick” urinary testing of school children or soldiers; or “opportunistic screening”, whereby 
27  
 
616 physician encounters for other medical reasons can be used to screen for CKD. Population-based 
 
617 screening can be further divided into general population screening or “targeted” screening of high- 
 
618 risk population groups (such as diabetic or family members related to subjects with diagnosed CKD). 
 
619 Unfortunately, the benefits and harms of both forms of screening for CKD have not been rigorously 
 
620 tested  in  long-term  prospective  studies,  so  the  overall  benefits  and  harms  of  population-based 
 
621 screening  for  CKD  are  poorly  understood  and  further  trials  are  needed  143, 144. Population-based 
 
622 screening for CKD is not recommended by the United States Preventive Task Force largely due to 
 
623 insufficient evidence of benefit (or harm) 145. Evidence in favor of case-finding (i.e., testing for CKD in 
 
624 people with recognized risk factors, such as hypertension or diabetes) is slightly better, but still 
 
625 incomplete. Accordingly, the American College of Physicians determined that current evidence was 
 
626 insufficient to evaluate the benefits (or harms) of screening and case-finding for CKD 146. The  position 
 
627 on screening for CKD varies widely around the world, with several countries having long-established 
 
628 programs  (Japan  and  Singapore  for  example)  and  others  that  have  introduced  them  as  part  of 
 
629 universal health care systems systems (The United Kingdom for example) 147-151. 
 
630 Both screening and case-finding for CKD are logistically hampered by the need for re- 
 
631 evaluation at a defined interval to fulfil the duration requirement for diagnosis. Therefore, one-off 
 
632 testing using  eGFR  or proteinuria has a  high  “false  positive” detection/diagnosis  rate, and possible 
 
633 misclassification of subjects by use of a fixed (non-age-sensitive) eGFR thresholds, as discussed. The 
 
634 potential harms of general population screening involve excessive follow-up diagnostic procedures, 
 
635 unnecessary referral of subjects erroneously diagnosed as having CKD, the anxiety induced by being 
 
636 labelled  as having CKD,  and potential impact  on  insurability.  Nevertheless, several  national kidney 
 
637 organizations advocate screening for CKD. Monte Carlo simulations support case-finding strategies in 
 
638 diabetic  subjects for albuminuria or hypertension  152, because  early treatment may  offer significant 
 
639 effects on delaying CKD progression and ESKD 153. Some studies have suggested that testing for 
 
640 abnormal albuminuria may be an efficient way of stratifying populations for more intensive search 
 
641 for modifiable risk factors for CKD and cardio-vascular events, such as hypertension and diabetes 154. 
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642 Indeed, abnormal proteinuria (even only slightly above the upper limit of normal) identifies people at 
 
643 greater  risk  for  ESKD  and/or  cardiovascular  morbidity  and  mortality  155.  As  mentioned  before, 
 
644 population screening for CKD using eGFR tends to substantially over-diagnose CKD in older subjects 
 
645 with  no  or  minimal  proteinuria.  Opportunistic  testing  for  CKD  has  much  merit,  especially  if the 
 
646 subjects have other  risk  factors  such  as diabetes,  hypertension,  or  a family history of CKD. In such 
 
647 patients an eGFR should be assessed along with an estimate of albuminuria or total protein excretion 
 
648 (“dipstick”), UACR or UPCR- adjusted for creatinine excretion rate). It also must be appreciated that 
 
649 older subjects with CKD G3 (as defined by KDIGO, see above) detected in screening programs or 
 
650 otherwise in primary care practices tend to have a rather benign prognosis, at least over the short 
 
651 term of 5 years or less.  Shardlow et al found  a very low rate of ESKD (0.2%) and stable or remission 
 
652 of CKD was found in 53% of such subjects (average age 73 years at entry) after 5 years of follow-up 
 
653 653 156. 
 
654 Finally, there are a few special circumstances where testing of apparently healthy individuals 
 
655 for CKD may be indicated. For example, first degree relatives of a patient with autosomal-dominant 
 
656 polycystic kidney disease (ADPKD) are eligible for screening with renal ultrasound or MRI regardless 
 
657 of results of eGFR or proteinuria. Siblings of patients with Fabry’s disease, Alport syndrome, or thin 
 
658 basement  membrane  nephropathy  might  also  benefit  from  genetic  analysis  as  well.  African- 
 
659 Americans with hypertension or HIV infection may receive more informed prognosis by assessment 
 






663 From a  societal  perspective,  prevention of CKD  is  preferable to  after- the-fact treatment  of kidney 
 
664 disease at its end-stage by dialysis or transplantation. Both primary prevention (occurring before CKD 
 
665 is established) and secondary prevention (initiated to slow the rate of CKD progression or to affect 
 
666 the associated co-morbidities or complications; see below, Management) should be considered. 
 
667 Primary prevention attacks the root causes of CKD and includes mitigating exposures to 
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668 nephrotoxic agents and events (Box 1). Reduction of the burden of infectious diseases (such as HIV, 
 
669 Malaria,  Streptococcus  infection)  have  already  yielded  some  protection  from  CKD,  but  many 
 
670 challenges  remain.  Preventing  obesity  and  the  associated  type  2  diabetes  mellitus  is  a  global 
 
671 challenge 158. The discovery of a central role for sugar and fructose intake and metabolism in obesity 
 
672 can be cited as an example of progress with implications for primary prevention. Indeed, better 
 
673 glycemic control may also eventually prevent CKD and its progression 153, 159-161. Improved recognition 
 
674 and reduction of the prevalence of AKI may also have dividends on prevention of CKD, especially in 
 
675 counties where AKI is common, under-recognized and under-treated such as equatorial Africa. Given 
 
676 the importance of low nephron endowment, fetal malnutrition and/or dysmaturity and manifested 
 
677 by  low  birth  weight,  global  efforts  to  reduce  fetal  malnutrition  and  dysmaturity  should  have 
 
678 enormous  “pay-back”  in  later years  and  focussed  effects  are beginning to  address this  important 
 




681 [H1] Management 
 
682 Several aspects need to be considered when managing patients with CKD: controlling nephron injury, 
 
683 normalizing single nephron hyperfiltration, controlling CKD-related complications, and preparing the 
 
684 patient  for  kidney  replacement  therapy.  At  the  core  of  these  is  the  principle  of  ‘the earlier-the 
 
685 better’, which is the effort to reduce the progression to ESKD and optimize renal outcomes. 
 
686 The impact of early therapy is well documented for Alport syndrome 162. Initiating RAS 
 
687 blockade based on the genetic diagnosis before any signs of kidney disease can have dramatic effects 
 
688 on renal outcomes, whereas initiating RAS blockade as late as CKD G3 only somewhat delayed ESKD 
 
689 (FIG. 6) 162. Further support comes from a posthoc analysis of clinical trials testing RAS blockade in 
 
690 diabetic kidney disease. The effect on gaining ESKD-free years was highest when RAS blockade was 
 
691 initiated at the time of microalbuminuria and lowest when initiated once a diagnosis of CKD G3 or G4 
 
692 was made 163. Therefore, early diagnosis and treatment are essential to prevent nephron loss  from as 
 





695 [H2]Controlling ongoing nephron injury 
 
696 Nephron injury can be driven numerous triggers (Table 1), and abrogating these triggers will slow 
 
697 progression to CKD and ESKD. For example, genetic abnormalities can cause CKD either by fostering 
 
698 nephrocalcinosis  164,  cystic  degeneration  or  by  weakening  epithelial  integrity  such  as  in  genetic 
 
699 podocytopathies or in abnormal processing or storage of metabolites or glycoproteins 78, 165. Specific 
 
700 cures for genetic kidney diseases exist in some forms and are mostly limited to enzyme replacement 
 
701 therapy or  substrate  supplementation  (Table  1).  The  genetic  basis  of immune-mediated  nephron 
 
702 injury is not yet fully explored but C3 glomerulonephritis or atypical hemolytic uremic syndrome 
 
703 (aHUS) can be controlled with complement inhibitors, an area of intense and promising research 166. 
 
704 Most acute forms of immune-mediated nephron injury present either as vasculitis, immune complex 
 
705 glomerulonephritis or interstitial nephritis (including allograft rejection). These disorders can often 
 
706 be targeted with immunomodulatory drugs (and sometimes with plasma exchange) to limit nephron 
 
707 loss from attack by the humoral and/or cellular elements of the immune system 167. 
 
708 In contrast, in smoldering immune injury, such as in chronic IgA nephropathy, it is difficult to 
 
709 dissect  CKD  progression  driven  by  immune  versus  non-immune  mechanisms  and  the  efficacy of 
 
710 immunosuppression versus RAS blockade and blood pressure control is less evident 168. Kidney biopsy 
 
711 may establish the diagnosis and can also guide management by assessing the ongoing activity of 
 
712 immune  injury  versus  irreversible  damage,  e.g.  in  lupus  nephritis,  IgA  nephropathy  or  allograft 
 
713 dysfunction.  Specific  treatments  are   also  available  for  CKD  related  to  urinary  tract  obstruction, 
 





injurious trigger, recovery of lost nephrons is impossible. 
 
717 [H3]Preventing any avoidable injury of remnant nephrons. 
 
718 Avoiding  further  episodes  of  AKI  is  crucial  to  minimize  stress  on  the  remnant  nephrons  in CKD 
 
719 kidneys.  This  implies  patient  education on avoidable nephrotoxins  such   as  radio  contrast  media, 
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720 NSAIDs, certain antibiotics or other endemic or occupational toxins. Hypovolemic states as well as 
 
721 urinary  outflow  obstruction should be  avoided. Additionally,  not every  asymptomatic  leukocyturia 
 
722 implies bacterial infection and antibiotic treatment should be limited to the presence of dysuria, 
 
723 bacteriuria, and leukocyturia. Smoking cessation is essential minimize CVD 169. 
724 
725 [H2] Normalizing single nephron hyperfiltration 
 
726 Rigorous RAS inhibition with ACE inhibitors (ACEi) or angiotensin receptor blockers (ARBs) has the 
 
727 capacity to substantially reduce SNGFR and glomerular filtration pressure, which leads to a decline in 
 
728 not only  proteinuria but also total GFR  — and,  hence, moderately increases  serum creatinine levels 
 
729 170.  At  first, this serum creatinine  increase  is  worrisome  to  patients  (and physicians)  and requires 
 
730 clarification that reducing hyperfiltration in remnant nephrons is the central strategy to retard CKD 
 
731 progression in patients with proteinuria. In contrast, ACEi or ARBs  do not retard the progression of 
 
732 non-proteinuric  forms  of  CKD  such  as  ADPKD  but  still  may  have  benefits  on  the  associated 
 
733 cardiovascular complications 171. ACEi or ARBs should be titrated to the maximal possible dose, while 
 
734 hyperkalemia  can  be  corrected  using  loop  diuretics  or  potassium-binding  resins  172.  A moderate 
 
735 increase in serum creatinine levels indicates a decline in SNGFR, which is a powerful predictor of the 
 
736 intended  nephroprotective  effect  173.  Numerous  RCTs  have  documented  the  class  effect  of  RAS 
 
737 inhibitors to retard or even halt CKD progression 44. Reducing dietary salt and drugs that support 
 
738 control of blood pressure and hyperlipidemia, often referred to as “remission clinic protocol”, may 
 
739 further reduce proteinuria and retard CKD progression 174, 175. Such interventions are affordable and 
 
740 are of importance where kidney replacement therapy is not available or affordable. 
 
741 Avoiding or correcting obesity can also reduce filtration load and glomerular hypertension; 
 
742 hence, a normal BMI is a treatment target to retard CKD progression 176. Any immunosuppression- 
 
743 related benefit of using steroids in CKD may be counterbalanced by steroid-related obesity that 
 
744 drives glomerular hyperfiltration and secondary FSGS, which could explain why steroid treatment 
 
745 falls short in retarding progression of IgA nephropathy-related CKD 168. Finally, concomitant diabetes 
32  
 
746 has   important   implications   for   CKD   management   177.   Hyperglycemia   maximizes   glomerular 
 
747 hyperfiltration  via  SGLT2-driven  vasodilation  of  the  afferent  arteriole  of  the  remnant  nephrons, 
 
748 which cannot  be controlled  by  RAS  inhibitors  94. Recently,  SGLT2  inhibitors  have  been  shown  to 
 
749 reverse this process and elicit profound additive nephroprotective effects on CKD progression 98, 178. 
 





for dual RAS/SGLT2 blockade in patients with diabetes and CKD. 
 
753 [H2]Controlling CKD complications 
 
754 CKD is associated with a number of secondary complications that require management (Box 3), the 
 
755 most relevant of which in terms of overall mortality is CVD 14. Cardiac and vascular alterations also 
 
756 arise from endocrine failure (e.g. lack of erythropoietin, vitamin D, parathyroid hormone), which 
 
757 causes anemia and secondary hyperparathyroidism 180. Myocardial fibrosis is the final consequence 
 
758 of the multiple underlying causes. 
 
759 Large randomized controlled trials in patients on hemodialysis have tested a number of 
 
760 different  interventions  intended  to  reduce  cardiovascular  events  such  as  dialysis  dose  and  flux, 
 
761 erythropoietin-stimulating   agents,   statins,   RAS   blockade,   folic   acid,   cinacalcet   or   vitamin   D 
 
762 derivatives   but   have   largely   been   unsuccessful   181-183.   For   example,   statins   may   prevent 
 
763 cardiovascular events in patients on dialysis, but the magnitude of any relative reduction in risk is 
 
764 substantially smaller as compared to what can be achieved in CKD 2-4 183-186. For example, reduction 
 
765 of LDL cholesterol with simvastatin plus ezetimibe reduced the incidence of major atherosclerotic 
 
766 events  more  efficiently  in  patients  with  CKD  G2-4  than  with  CKD  G5  or  5D  183.  Hence,  early 
 
767 intervention with standard-of-care is essential in patients with CKD 2-4. In parallel, similar concepts 
 
768 for cardiovascular protection are administered for progression of diabetic and non-diabetic kidney 
 
769 disease. For these patients, guideline-directed approaches to achieve target blood pressure through 
 
770 administration of RAS blockers, salt restriction and anemia prevention is the mainstay of therapy 187, 
33  
 
771 188. Guidance is also available for the correction of acidosis and mineral and bone metabolism 
 




774 [H2]Preparing for kidney replacement therapy 
 
775 ESKD typically requires renal replacement therapy, although conservative treatment is a potential 
 
776 alternative option, especially in older adults with limited life span. Counseling on the options (kidney 
 
777 transplant, hemodialysis, peritoneal dialysis or no dialysis) should be coordinated by the nephrologist 
 
778 and involve a multidisciplinary team including the general practitioner. Early counseling is essential 
 
779 because informed patients are better prepared to face kidney failure. Indeed, late referral, i.e. at the 
 
780 time of ESKD, is associated with worse health status at the time of kidney replacement therapy 
 
781 initiation, higher mortality  after starting dialysis,  and decreased  access  to transplant  190.  However, 
 
782 one of the biggest challenges nephrologists face is to predict kidney disease progression, which does 
 
783 not follow a steady linear decline. This unpredictability often becomes a barrier to timely shared 
 
784 decision making between  patients and  physicians and  could  lead  to  adverse patient  outcomes 190, 
 
785 and may offset the relationship between the early pre-dialysis nephrology care for adults with late 
 
786 stage  of CKD  and  improved  outcomes  191  KDIGO  suggested that  dialysis be  initiated  when one or 
. 
 
787 more of the following are present: symptoms or signs attributable to kidney failure (serositis, acid- 
 
788 base or electrolyte abnormalities, pruritus); inability to control volume status or blood pressure; a 
 
789 progressive  deterioration  in  nutritional  status  refractory  to  dietary  intervention;  or  cognitive- 
 
790 impairment   1.   This   often   but   not   invariably   occurs   in   the   GFR   range   between   5   and  10 
 
791 ml/min/1.73m2.  Moreover,  living  donor  preemptive  renal  transplantation  in  adults  should  be 
 
792 considered when the GFR is <20 ml/min/1.73m2, and there is evidence of progressive and irreversible 
 






796 In 1945 Willem Kolff was the first to successfully treat kidney failure of a patient by performing 
34  
 
797 hemodialys using an artificial kidney able to clear blood from uremic toxins 192.  Since then numerous 
 
798 technical innovations have optimized the procedure that meanwhile has become available (but not 
 
799 everywhere affordable) all over the world 38. Preparing patients for hemodialysis involves referral for 
 
800 vascular access placement. The types of access include arteriovenous fistulae, arteriovenous grafts 
 
801 and central venous catheters (which are for short-term use) (FIG. 7A-C); arteriovenous  access is the 
 
802 preferred  option  for  hemodialysis,  although  there  is  no  consensus  about  the  optimal  timing for 
 
803 creation, especially for arteriovenous fistulae 193. To protect the blood vessels for permanent vascular 
 
804 access,  attention  should  be  taken  to  avoid  venous  puncture  or  intravenous  catheter  placement 
 
805 proximal to the wrist, which implies that venous puncture at the back of the hand still being possible. 
 
806 Arteriovenous  access  (either  fistulae  or  grafts)  is  associated  with  better  outcomes  than   central 
 
807 venous catheters 194 195. Patients with a central venous catheter have poorer survival than those who 
 





is preferable for all patients in which the vascular status allows to install a fistula. 
 
811 [H3]Peritoneal dialysis. 
 
812 Peritoneal dialysis is another way to eliminate uremic toxins from the blood using the 
 
813 peritoneal membrane as an exchange interface. For this a transcutaneous catheter is implanted into 
 
814 the peritoneal cavity that allows repetitive daily drainage and refills of dialysate fluid. After some 
 
815 hours of reaching equilibrium between uremic blood and fresh dialysate each dwell is expected to 
 
816 drain excess fluid, metabolic waste products including uremic toxins (FIG. 7D). There are published 
 
817 guidelines  regarding  insertion  and  perioperative  management  of  peritoneal  dialysis  catheters.  A 
 
818 peritoneal dialysis catheter may be ready for use after 2 to 3 weeks. However, there is marked 
 
819 variability in peritoneal dialysis catheter insertion techniques (open surgery, blind via trocar or blind 
 
820 via  Seldinger  technique)  and  perioperative  management  197.  Interestingly,  patients  starting  on 
 
821 peritoneal dialysis show better initial outcome and preservation of residual renal function, especially 
 





824 [H3]Kidney transplantation. 
 
825 When available, suitability for kidney transplantation should be evaluated according to age and co- 
 
826 morbidities,  but  it  may  take  months  to  complete  199.  Co-morbidities  such  as  cancer,  chronic 
 
827 infections,  cardiac  or  peripheral  vascular  disease,  and  the  risk  for  medical  noncomplicance  are 
 
828 carefully evaluated in this process. Depending on the regional ratio of donors to recipients and on 
 
829 allocation rules, waiting time for a deceased donor kidney can vary from a few months (e.g. Belgium, 
 
830 Austria) to many years (e.g. Germany). Thus, the option of living kidney donation should be explored. 
 
831 To test for eligibility, potential donors must undergo a comprehensive health assessment 
 
832 including  tests  for  blood  group  and  human  leukocyte  antigen  compatibility  with  the  potential 
 
833 recipient, GFR measures, imaging of the kidneys and the urinary tract, cardiac testing, and other tests 
 
834 depending on the medical history. This is because, the donor's short and long-term well-being after 
 
835 donation  remains  a  first  priorityPre-emptive  transplantation  (kidney  transplantation  before even 
 
836 initiating  dialysis)  may  offer  several  benefits  to  ESKD  patients  but  its  impacts  remain  under 
 
837 evaluation 200. The half-life of a transplanted kidney is <20 years, making these patients also potential 
 
838 candidates for CKD treatments during their life span 201. For example, recurrent glomerulonephritis is 
 
839 an unpredictable complication that can have a negative impact on graft outcome 202. 
840 
841 [H2]Conservative treatment/palliative care 
 
842 Kidney replacement therapy may not be available or affordable but it may also not be advisable for 
 
843 medical reasons. Especially in very old ESKD patients, dialysis may neither increase life span nor 
 
844 improve quality of life (QOL) 203-205: in such cases palliative (trying to control the symptoms of uremia 
 
845 affecting QOL 206) and education starting at CKD G4 (aimed at explaining comorbidity management) 
 
846 may  be  appropriate.  Withdrawal  from  dialysis  is  a  related  issue  and  is  common  in  very  old 
 





849 [H1] Quality of life 
 
850 CKD-related symptoms increase along CKD progresses and are key drivers of poor QOL in patients 
 
851 with  CKD  and  ESRKD  208-210.  In  contrast,  symptoms  rapidly  improve  upon  kidney transplantation. 
 
852 Symptoms  are  most  severe  in  dialysis  patients,  who  frequently  report  fatigue,  nausea, dyspnea, 
 
853 anorexia,  pruritus,  restless  legs,  and  cramps  211.  Pain  is  especially  common:  in  a  survey  of  205 
 
854 prevalent patients on hemodialysis, approximately 25% had “severe” pain during the 24h preceding 
 
855 the  interview,  and  an  additional 12% had  “moderate pain” 212. Mental  illness  including depression 
 
856 and anxiety are also common 213, but are understudied among people with CKD. Unfortunately, 
 
857 clinical  and  epidemiological  characteristics  associated  with  the  presence,  severity,  onset  and 
 
858 remission   of   uremic   symptoms   are   incompletely   described;   their   pathophysiology   is  poorly 
 
859 understood; and few drugs have been approved by regulatory authorities for their treatment 214. 
 
860 Comorbidity and complications of CKD also substantially contribute to the reduced QOL in 
 
861 CKD patients. In some cases (e.g. anemia), effective treatments are available. In others, treatment is 
 
862 technically possible but has significant limitations, and treatment itself frequently causes additional 
 
863 symptoms and morbidity (e.g. dialytic management of hypervolemia). Despite the best efforts of 
 
864 clinicians, interactions between complications and their treatments can further compromise QOL for 
 
865 patients   (e.g.   volume   overload   resulting   from   sodium   bicarbonate   treatment   of   acidosis). 
 
866 Management of multiple comorbid conditions is already complex in patients with normal kidney 
 
867 function 215; the situation is even more challenging in people with CKD, where the pathophysiology 
 
868 and optimal treatment of common coexisting conditions may differ from the general population (e.g. 
 
869 statins  for  coronary disease  in  dialysis patients). Lack  of  knowledge  about  how  to  prioritize  and 
 
870 manage comorbid conditions undoubtedly contributes to the lower QOL in CKD patients through 
 
871 multiple  mechanisms   –   including   drug-drug  and   drug-condition  interactions;   pill  burden;   and 
 
872 decisional conflict for patients. 
 
873 Dialysis is an effective life-support treatment but has many limitations in addition to those 
 
874 mentioned above. Key challenges for hemodialysis that specifically compromise QOL include poor 
37  
 
875 functional status (driven in part by procedure-related immobilisation, uremia-related malnutrition, 
 
876 and muscle wasting), the intrusive and time-consuming nature of the treatment, and vascular access 
 
877 infection and dysfunction 216. Instruction for some home-based, low intensity physicial exercise can 
 
878 improve physical performance and QOL in patients on hemodialysis 217. Peritoneal dialysis also poses 
 
879 significant  challenges  for  QOL  including  gastrointestinal  distension,  hernias,  and  chronic  volume 
 
880 overload. Both forms of dialysis make employment difficult and both are associated with a high 
 
881 prevalence of infectious complications and undue pill burden. Some studies suggest that peritoneal 
 
882 dialysis  is  associated  with  slightly  better  QOL  than  hemodialysis  218,  but  it  is   possible  that  this 
 
883 observation  is  confounded  by  patient  characteristics  219.  Home  dialysis  strategies  are constantly 
 
884 improving and are becoming possible tools to improve QOL 220. Kidney transplantation is associated 
 
885 with substantially better QOL than either form of dialysis 221, but even recipients with good graft 
 




888 Recent emphasis on patient-centred research should help to improve QOL for people with 
 
889 CKD by increasing the likelihood that important but understudied issues such as symptom control are 
 
890 studied and new solutions are identified. In addition, findings from patient-centred research should 
 
891 help  to  drive  uptake  of  patient-centred  care  at  the  bedside,  especially  if  supported  by patient- 
 





important issues such as reduced QOL. 
 
895 [H1] Outlook 
 
896 There are many unmet medical needs in nephrology as a specialty and improving and refining our 
 
897 understanding  of  disease  mechanisms  in  common  and  rarer  conditions  is  lacking,  as  are  novel 
 
898 therapies to treat rarer and common causes of kidney disease progression and a culture of curiosity 
 
899 and clinical trials that advance the field 37. Key areas are to improve the identification of CKD and to 
 
900 reduce  CKD  risk  factors,  to  improve  the  understanding  of  causes  and  consequences  of  CKD, to 
38  
 
901 improve  outcomes  with  current  knowledge,  and  finally  to  develop  and  test  new  therapeutic 
 
902 strategies 37. Here, we highlight eight promising domains expected to produce significant impact on 
 





905 [H2]How genetic kidney disease contributes to CKD 
 
906 Genetic abnormalities were identified in 20% of CKD cases in children, adolescents, and young adults. 
 
907 Next generation sequencing have unveiled the extreme genetic heterogeneity of kidney disease.  For 
 
908 example  more  than  40  different  genes  were  discovered  as  possible  causes  of  steroid-resistant 
 
909 nephrotic syndrome 142. This requires implementation of current diagnostic strategies that go beyond 
 
910 th renal biopsy and open to personalized diagnosis and treatments 142. In addition, first genetic 
 
911 modifiers of CKD progression such as APOL1 or UMOD have been identified in older adults. CKD in 
 
912 adults may also relate to (genetically- or environmentally-defined) low nephron endowment or AKI 
 
913 episodes early in life, e.g. as early as during neonatal (intensive) care. Thus, CKD in adults, often 
 
914 classified by a single diagnosis, may often be the consequence of several components accumulating 
 
915 with time, a conclusion having important implications for the design of CKD trials, e.g. in prevalent 
 
916 entities such as “diabetic nephropathy”. Progress will require identifying the cause(s) of CKD and 
 
917 dissecting   modifiable   from   non-modifiable   drivers   of   CKD   progression   as   well   as   specific 
 
918 pathophysiological mechanisms that might help to define more homogeneous patient subgroups. 
 
919 The identification of such subgroups is a prerequisite to conducting more targeted clinical trials, 
 
920 which  require  fewer  participants  and  increase  the  possibility  to  identify  appropriate  drugs  for 
 
921 different subtypes of patients. Patient heterogeneity is considered one of the main reasons why 
 
922 clinical trials in nephrology commonly fail 223. Genetic investigations might therefore not only hold 
 
923 promise for individual patients, for example by facilitating the diagnosis of a monogenic disease with 
 
924 potential  implications  for  individualized  treatment,  but  might  also  improve  classification  and 
 
925 ultimately   treatment   and/or   prevention   in   groups   of  patients  224.   The   study   of   the genetic 
 
926 predisposition to kidney diseases has made major progress over the past decade. For the first time, 
39  
 
927 researchers have been able to carry out genome-wide screens to study complex kidney diseases, to 
 
928 which genetic susceptibility variants in many genes, as well as environmental factors, contribute. 
 
929 Genome-wide association studies (GWAS) have emerged as an important method to map risk loci for 
 
930 complex dis- eases by  investigating  the association  of genetic  markers across  the genome  with the 
 
931 disease of interest. We can predict that the list of genetic forms of CKD will exponentially increase 
 







935 [H2]Biomarkers for CKD management 
 
936 As discussed,  using  serum  creatinine-based diagnosis implies diagnosis  as late as CKD G3,  leaving a 
 
937 small  window  of  opportunity  for  modulating  CKD  progression.  Earlier  identification  CKD  with 
 
938 biomarkers   that   can   also   predict   CKD   progression   would   help   to   initiate  nephroprotective 
 
939 interventions 37. Most attractive would be a marker of nephron number. Defining nephron number at 
 
940 birth would display low nephron endowment and help to dissect it from injury- or ageing-related 
 
941 nephron loss later in life. A marker of nephron number would detect CKD G2 and could serve as an 
 
942 end point parameter for clinical trials to quantify nephro-protective effects or drug toxicity. However, 
 
943 identifying  a  clinically  applicable  biomarker  of  nephron  number  in  serum  or  urine  has  been 
 
944 unsuccessful so far. Biomarkers do not clearly discriminate nephron number from the compensatory 
 
945 increase in mass of remnant nephrons upon injury (remnant nephron hypertrophy). Imaging studies 
 
946 with tracers or the combination of imaging with kidney biopsy indicating the number of glomeruli 
 
947 and even SNGFR are promising as a proof-of-concept 85, 225. 
948 
949 [H2]Separating triggers of nephron loss from CKD progression 
 
950 Congenital    low    nephron    endowment,    obesity,    and    AKI/CKD-related    nephron    loss    imply 
 
951 hyperfiltration and hypertrophy of the remnant nephrons, which in turn promote secondary FSGS 
 
952 and  further  nephron  loss.  Interstitial  fibrosis  most  likely  represents  matrix  replacement  of  lost 
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953 nephrons,  thereby stabilizing the remnant  nephrons.  Whether  fibrosis itself contributes to nephron 
 
954 loss remains under debate and several antifibrotic drugs are under study to test this concept 226, 227. 
 
955 Dissecting   the   relative   contribution   of   nephron   injury,   wound   healing,   and   compensatory 
 
956 hyperfiltration remains notoriously difficult in clinical practice. Finding ways to define their relative 
 





for the following years. 
 
960 [H2] Modifying CKD progression 
 
961 Among the many ideas on how to potentially modulate CKD progression some accumulated a large 
 
962 fundament  of  experimental  evidence  but  still   await  successful   validation   in   human   RCTs (e.g. 
 
963 protecting  nephron  loss  by  modulating  kidney  fibrosis)  228.  In  contrast,  the  idea  to  retard  CKD 
 
964 progression with urate-lowering therapies already showed promising results in smaller trials and the 
 
965 results of ongoing multicenter RCT are eagerly awaited 229. In contrast, the nuclear factor (erythroid- 
 
966 derived    2)-like    (NRF)-2    agonist    bardoxolone    or    folic    acid    supplementation    have  shown 
 
967 nephroprotective effects in RCTs in some populations but their mechanisms-of-action are not yet 
 




970 [H2]Nephrogenesis and regeneration 
 
971 Given the significant hurdles preventing widespread use of renal transplantation, Current work is 
 
972 exploring whether the transfer of autologous stem (progenitor) cells, stromal cells or other cell types 
 
973 can support the regeneration of injured nephrons (FIG. 8). For this to be a viable option, a growing 
 
974 research  field  is  trying  to  unravel  the  physiology  and  pathophysiology  of  the  nephron’s intrinsic 
 
975 capacity to regenerate. 
 
976 Several   studies   have   identified   possible   drugable   targets   to   specifically   enhance   nephron 
 
977 regeneration  with  pharmacologic  intervention  to  prevent  nephron  loss  in  AKI  and  CKD  232.  In 
 
978 particular, targeting parietal epithelial cells that can act as progenitor for podocytes, to promote 
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979 their differentiation into fully functional podocytes and/or to block their excessive proliferation and 
 
980 matrix  production  can  promote  remission  of  glomerular  disorders  233-235.  In  addition,   enhancing 
 
981 tubular regeneration by promoting tubular epithelial cell proliferation can reduce the occurrence of 
 
982 CKD after AKI  234, 236. Although  in vivo  experimental studies  appear promising,  no  clinical  trials are 
 
983 available  yet  233-235.  Finally,  numerous  Inhibitors  of  maladaptive  repair  induced   improved  tissue 
 
984 structure and even function in experimental models of CKD. Several phase 1-2 clinical trials were 
 
985 started but up to now, but none progressed beyond phase 2 237. However, other new antifibrotic 
 
986 drugs display are currently being tested in clinical trials 234, 237, 238. 
 
987 Regenerative   medicine   is  also   being   explored  for  treatment   of  kidney   disorders.  Therapeutic 
 
988 properties mesenchymal stroma cells (MSC), a population of well-characterized, easily obtainable 
 
989 cells  with  effective  in  numerous  but  not  all  experimental  models  of  CKD  239,  240.  The underlying 
 
990 mechanisms  of  action  of  the  MSC  have  been  extensively  described  and  consist  essentially  in 
 
991 immunomodulatory   and   paracrine   effects.   Similarly,   numerous   experimental   studies reported 
 
992 improvement  of kidney  function and/or structure by using injection of human  renal progenitors  232- 
 
993 236. However, the translation of preclinical studies into robust, effective, and safe patient therapies 
 
994 remains limited 233, 234, 237. 
 
995 Finally, the generation of 3D organ-buds termed 'organoids' from human induced pluripotent stem 
 
996 cells and embryonic stem cells was achieved also for the kidney; these organoids consist of a variety 
 
997 of renal cell types in vitro that mimic organs in vivo 241, 242. The organoid bears great potential in the 
 
998 study of human diseases in vitro, especially when combined with CRISPR/Cas9-based genome-editing 
 
999 243, 244. However, the complexity of kidney structure and function is yet far from being reproduced for 
 





eventually possible is still open. 
 




1004 Innovative approaches to better link translational research to clinical trial findings will need to start 
1005 with well-defined human genotypes and phenotypes to identify molecular targets, which may (or 
1006 may not) subsequently be validated in animal models. Selecting such animal models for validation 
1007 should be based on models that recapitulate CKD progression in humans and applying identical end 
1008 points in subsequent clinical trials. This may include mice with identical pathogenic mutations as in 
1009 human genetic kidney disease as being available for Alport syndrome, mouse models with a partial 
1010 human immune system, or eventually experimentation in pigs or primates to close gaps between 
1011 preclinical and clinical trials 245, 246. 
1012 In addition, trial design may be improved upon reconsidering disease definitions, avoiding 
1013 add-on designs using drugs with redundant mechanisms-of-action, preselecting patients with drug 
1014 mechanisms-related biomarkers, and of study end points that better predict CKD progression to 
1015 ESKD. For example, in order to test efficacy of the C5a receptor inhibitor avacopan in ANCA vasculitis 
1016 the CLEAR trial at first avoided the usual add-on standard of care approach and compared instead 
1017 avacopan plus low-dose steroids versus placebo plus high dose steroids on top of either 
1018 cyclophosphamide or rituximab 247. This way it was proven that avacopan is effective in replacing 
1019 high-dose glucocorticoids in treating vasculitis. 
1020  
1021 [H2]Limiting cardiovascular morbidity and mortality 
1022 Targeting the association of CKD with cardiovascular morbidity and mortality will require more 
1023 functional studies in animals and humans to identify molecular targets potentially suitable for 
1024 therapeutic interventions 37. Controlling hyperlipidemia with PCSK9 inhibitors, suppressing systemic 
1025 inflammation with innovative anti-inflammatory drugs, modulating the intestinal microbiota, or 
1026 directly modulating vascular calcificaton and cardiac fibrosis may offer new solutions for this eminent 
1027 problem in the future. 
1028  




1030 The ever growing complexity of kidney biopsy reading, lab diagnostics, and the increasing need for 
1031 genetic testing will require centers of excellence with sufficient resources to meet the diagnostic 
1032 demands. The same may apply to upcoming costly therapies, where patient selection is of particular 
1033 importance. Educational efforts are also needed to alert patients and general physicians to the 
1034 increasing number of more affordable therapeutic options for CKD patients with diabetes, such as 
1035 SGLT2 inhibitors. Finally, national CKD registries and treatment guidelines advocate awareness in the 
1036 public, among health care providers, and decision takers, which can generate important support for 
 
1037 implementation of standards 37. Global guidelines created by the KDIGO initiative have become 
 
1038 instrumental in this process starting from a global definition of CKD stages up to defining standards 
 
1039 for the management of CKD complications (Box 3). In addition, global initiatives on CKD launched by 
 





them in the future 37. 
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• Diabetes mellitus (type 1 or 2) 
 




• Monogenetic kidney disease (for example, autosomal dominant polycystic kidney disease, 
 





syndrome, complementopathies such as atypical haemolytic-uremic syndrome (aHUS) 
 
• Prolonged exposure to nephrotoxins (e.g., chemotherapy for cancer treatment, proton pump 
 







herbs, agricultural chemicals, heavy metals, irradiation) 
 
• Climate (excessive heat exposure and dehydration) 
 





















































































• Low nephron endowment at birth (low birth weight, fetal dysmaturity) 
 
• Obstructive uropathy 
 












1079 • Fluorescent anti-nuclear antibody, anti-dsDNA antibody, anti-phospholipaseA2 receptor 
1080 antibody, anti-GBM antibody, anti-neutrophil cytoplasmic antibody, anti-phospholipid 
1081 antibody 






1084 • Serum free light chains, serum or urinary immunofixation (multiple myeloma) 






1087 • Human Immunodeficiency Virus, hepatitis B virus, hepatitis C virus serology, CD4+ T cell 




[H1]Monogenetic kidney disease 
 
1090 • Serum or urinary enzymes, glycolipids 







1093 Box 3. Key strategies to managing CKD complications 
 
1094 [H1]Renal anemia 187 
1095 • Erythropoeiesis stimulating agents (ESAs) are only given once all correctable causes of 
1096 anemia (e.g. iron deficiency and inflammatory states) have been addressed 
1097 • Adults received Iron supplementation when transferrin saturation is <30% and ferritin <500 
1098 ng/ml; children (<18 years) receive Iron supplementation when transferrin saturation is 
1099 <20% and ferritin <100 ng/ml 
1100 • ESAs may be used to avoid hemoglobin <9.0 g/l with a target of max.11.5 g/dl 
1101 • Avoid blood transfusion whenever possible, especially in potential transplant recipients. 
1102 Caution in giving ESAs in people at risk of stroke or who have malignancy 
1103 [H1]Arterial hypertension 188 
 
1104 • Individualize blood pressure (BP) targets are based on age and co-morbidities, with special 
1105 recommendations for diabetes 
1106 • Targets include normalizing body weight (BMI 20-25), NaCl intake (<5g/d), achieving regular 
1107 physical exercise, limiting alcohol intake to 2 drinks/d (men), 1 drink/day (women) 
 
1108 [H1]Mineral and bone disorder 189, 248 
 
1109 • Monitor calcium, phosphorus, parathyroid hormone, and alkaline phosphatase activityin 
1110 adults beginning in CKD G3a and in children beginning in with CKD G2 ; 25(OH)D levels 
1111 might also be measured and corrected by vitamin D supplementation as for the general 
1112 population 
1113 • In CKD G3a-G5D lower elevated phosphate levels toward the normal range but avoid 
1114 hypercalcemia by restricting the dose of calcium-based phosphate binders 
1115 • Avoid long-term exposure to aluminium in phosphate binders or dialysate 
1116 • Measure bone mass density in patients with CKD G3a-G5D with evidence of bone disease to 
1117 assess fracture risk if results will impact treatmentIn adults calcitriol and vitamin D 
48  
 





hyperparathyroidism in CKD G4-G5 is severe and progressive 
 





analogs are recommended 
 
• Consider patients with vascular calcifications at high risk for cardiovascular disease; avoid 
 
1123 calcium-based phosphate binders in these patients, limit dietary phosphate intake. 
 
1124 [H1]Hyperlipidemia 249 
 





statin/ezetimibe combination should be given 
 
• Adults <50y with CKD and other cardiovascular risk factors should receive a statin 
 
 
1128 [H1]Metabolic acidosis 
 
1129 • Oral bicarbonate can be used to correct mild metabolic acidosis 
 
 
1130 [H1]Chronic hyperkalemia 
 







































1142 Figure legends 
1143  
1144 Figure 1. Kidney Disease Improving Global Outcomes (KDIGO) classification of chronic kidney 
1145 disease (CKD). The 2D matrix illustrates the predictive value of different levels of albuminuria and 
1146 estimated glomerular filtration rate (eGFR). The color code indicates the risk for CKD progression to 
1147 end-stage kidney disease (ESKD) and overall mortality. This matrix defines different stages of CKD 
1148 referred as, for example, CKD G2A2 whereby the eGFR is 60-89 ml/min/1.73m2 albuminuria is 
1149 moderately increased; such a patient would have a moderately increased risk of progressing to ESKD. 
1150 This staging system for CKD G2-G4 may underestimate the extent of irreversible nephron loss 251. 
1151 That is, if total GFR relies on the single nephron GFR (SNGFR) and the number of nephrons, SNGFR 
1152 has to increase to compensate for reduced (or declining) number of nephrons to maintain total GFR. 
1153 However, such a compensation may not occur with physiological ageing 85. Additionally, total GFR 
1154 drops if remnant nephrons are not able to increase SNGFR. Finally, increases in serum creatinine 
1155 levels (representing a GFR of ≤40%) may imply remnant nephrons of ≤30% of a “normal” nephron 
1156 number. Furthermore, the prognosis facet of CKD classification has been developed by large-scale 
1157 population-based epidemiological studies, which suffer from a “false positive” rate of- approximately 
1158 30-35% as in such studies repeat analysis after 3 months was often not available 43. Reprinted with 
1159 permission  from Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. 
1160 KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. 
1161 Kidney Int Suppl. 2013;3:1-150. 
1162  
1163 Figure 2. Global prevalence of treated end-stage kidney disease per 1 million population. The map 
1164 depicts the prevalence of renal replacement therapy represented by kidney replacement therapy 
1165 (kidney replacement therapy: hemodialysis, peritoneal dialysis, and kidney transplantation), for 
1166 [Au:OK?ok] ESKD per 1 million population based on individual country data. Data not available 




1168 received the survey. Reprinted with permission  from Bello, A. K. et al. Assessment of 
1169 Global Kidney Health Care Status. JAMA 317, 1864-1881 (2017 
1170  
1171 Figure 3. Glomerular filtration rate (GFR) over time and impact of low birth weight on progression 
1172 of CKD. A. Population studies assessing estimated GFR document a decline in eGFR with age; here 
1173 the data in men from Marocco are shown 43. P values from P03-P97 represent the percentiles of the 
1174 entire population with P50 representing mean values. This decline is a consequence of loss of 
1175 functioning nephrons via glomerulosclerosis-related nephron atrophy and is not accompanied by a 
1176 compensatory increase in SNGFR in the remaining intact nephrons, unlike what occurs when 
1177 nephrons are lost by injury or surgery 42, 52, 85. At age 70, nephron number is around 50% of that at 
1178 age 25. Whether or not this implies increased SNGFR (single nephron hyperfiltration) of remnant 
1179 nephrons or mirrors the declining demand for filtering metabolic waste is under debate but will 
1180 strongly depend on co-morbidities such as obesity and the life time history of acute kidney injury 
1181 episodes. In such cases, SNGFR should correlate with the total number of nephrons per body mass. B: 
1182 Low birth weight (LBW) increases four-fold the relative risk to develop CKD by the age 17 as shown 
1183 by population studies 69. C: LBW status also significantly shortens the time span of when patients 
1184 with IgA nephropathy reach end stage kidney disease 70. 
1185  
1186 Figure 4. Contributing factors to nephron loss. In addition to ageing, acute and chronic forms of 
1187 kidney injuries further may contribute to nephron loss along life time. Environmental, genetic causes 
1188 and systemic disease-related reasons for low nephron endowment or causes of nephron injury are 
1189 shown during the different phases in life, when they are most commonly (but not exclusively) 
1190 encountered. Combinations of such causes determine the individual risk for CKD throughout life. For 
1191 example, congenital abnormalities of the urinary tract (CAKUT) can lead to end stage kidney disease 
1192 (ESKD) early in life, or to secondary focal segmental glomerulosclerosis (FSGS)-related ESKD later in 




1194 can also influence risk, as can infections (bacterial, parasitic, viral). Severe genetic defects that lead to 
1195 FSGS, Alport syndrome, cysts and atypical hemolytic uremic syndrome typically become evident early 
1196 in life, whereas moderate genetic defects (such as mutation in UMOD) can become evident in 
1197 adulthood. Genetic variants in genes such as APOL1 can modify the course of diseases such as lupus 
1198 nephritis. 
1199  
1200 Figure 5. Injury, hyperfiltration and hypertrophy of the nephron. A | In response to nephron loss, 
1201 single nephron hyperfiltration induces an increase in nephron size as a compensatory mechanism to 
1202 maintain overall renal function. Accordingly, podocytes need to undergo hypertrophy to maintain the 
1203 filtration barrier of the increasing dimensions of the filtration surface. However, podocyte 
1204 hypertrophy is limited; beyond a certain threshold, barrier dysfunction first manifests as mild to 
1205 moderate proteinuria. At later stages the increasing podocyte shear stress promotes podocyte 
1206 detachment. Parietal epithelial cells (PEC) host putative podocyte progenitors but proteinuria and 
1207 potentially other factors inhibit their potential to replace lost podocytes and rather promote scar 
1208 formation, i.e. focal segmental glomerulosclerosis (FSGS). B | Hyperfiltration and proteinuria both 
1209 imply an increased reabsorption work load for proximal tubules. Activated tubular cells secrete pro- 
1210 inflammatory mediators that promote interstitial inflammation. Together with the progression from 
1211 FSGS to global glomerulosclerosis the inflammatory microenvironment of the tubulointerstitium 
1212 promotes tubular atrophy and interstitial fibrosis. Scar formation is associated with vascular 
1213 rarefication and ischemia. The remnant nephrons have to further increase in size to meet the 
1214 filtration demands, which accelerates the aforementioned mechanisms of CKD progression in a 
1215 vicious circle. 
1216 Figure 6. The earlier-the-better: renal outcome depending on when starting renin-angiotensin 
1217 system (RAS) blockade in Alport Syndrome. As shown, the time to renal replacement therapy was 
1218 longest for those who started RAS inhibition early, at onset of microhematuria (usually at birth) or 




1220 macroproteinuria (>0.3g/day or per gram creatinine (green curve)) or CKD G3/4 has been established 
1221 considerably shortens the time to renal replacement. Untreated patients (red curve) are relatives to 
1222 Reprinted with permission from Gross, O. et al. Early angiotensin-converting enzyme inhibition in Alport 




1226 Figure 7. Access for hemodialysis or peritoneal dialysis. A | Arteriovenous fistulae are created by 
1227 surgical anastomosis of a peripheral artery with a larger subcutaneous vein, e.g. at the forearm. The 
1228 increased flow and perfusion pressure leads to structural modifications in the draining vein allowing 
1229 repetitive venous puncture for hemodialysis. Sometimes declining blood flow to the hand and fingers 
1230 (steal phenomonen), compensatory increases in cardiac output or aneurysm formation cause 
1231 problems and require surgical correction. B | Arteriovenous grafts may become necessary when the 
1232 patient`s vascular status does not allow to build a fistula. Polytetrafluoroethylene grafts are mostly 
1233 used and can be repetitively punctured for hemodialysis. Common problems are sterile inflammatory 
1234 postimplantation syndromes or prosthetic graft infections causing bacterial sepsis. C | Central 
1235 venous catheters become necessary when immediate initiation of renal replacement therapy is 
1236 needed up to when a fistula or graft implant becomes ready for use. Such catheters may remain the 
1237 last vascular access option for patients in which the vascular or cardiac status does not allow fistula 
1238 or graft placement. Catheter infections or thrombotic complications remain constant concerns. 
1239 Peritoneal dialysis requires placement of a transcutaneous catheter into the peritoneal cavity. This 
1240 catheter allows fills, drains and refills of dialysate while the peritoneum serves as exchange 
1241 membrane with the uremic blood. Fluid drains and refills with fresh dialysate are needed in regular 
1242 intervals, usually 4 times a day. 
1243  
1244 Figure 8. Targeting kidney regeneration. In the future, it may be possible to target kidney 
1245 regeneration and maladaptive repair to minimize the loss of injured nephrons and to protect the 
54  
 
1246 remnant  nephrons.  Here,  the  most  promising  arenas of  research  include:  1.  Enhancing podocyte 
 
1247 regeneration. This aim may be achieved by drugs that promote differentiation into podocyte of 
 
1248 parietal epithelial cell (PEC) progenitors of the Bowman’s capsule and/or blocking their excessive 
 
1249 proliferation. 2. Blocking fibrosis and/or maladaptive repair by inhibiting fibroblast expansion. 3. 
 







1253 Figure 9. Cell therapy and organoids as potential tools in CKD research and therapy. (A) Injection of 
 
1254 two cell types, mesenchymal stromal cells and renal progenitors, were reported as possible tools for 
 
1255 cell therapy of CKD, improving kidney function and structure in animal models. Numerous phase 1-2 
 
1256 clinical  trials  are  ongoing.  Several  mechanisms  were  proposed  to  explain  the  beneficial  effects 
 
1257 observed, mostly based on secretion of paracrine factors and/or microvesicles. For renal progenitors 
 
1258 also direct engraftment  in the injured  tissue was reported. (B) Kidney  organoids were  generated  in 
 
1259 vitro starting from induced pluripotent stem cells (iPSC) and embryonic stem cells (ESC) and used for 
 




























Table 1. Therapeutic interventions for selected conditions associated with CKD risk 
 
Disease entity Diagnostic test Therapeutic interventions 
Genetic injury   
Polycystic kidney disease Echography or MRI to detect cysts Tolvaptan (vasopressin receptor 2 
antagonist of benefit in selected 
patients) 
Alport syndrome Genetic testing for collagen 
mutations 
ACE inhbitors to reduce filtration 
pressure in remnant nephrons 
Fabry disease Serum alpha-galactosidase activity Alpha-galactosidase replacement 
therapy 
Primary hyperoxaluria Echography to detect 
nephrocalcinosis, urinary oxalate 
levels, genetic testing for serine— 
pyruvate aminotransferase , 
glyoxylate 
reductase/hydroxypyruvate 
reductase, and dihydrodipicolinate 
synthase-like 
Increase fluid intake, 
supplementation with potassium 
citrate, magnesium oxide, 
pyridoxine , and orthophosphate, 
oxalate-reduced diet, liver 
transplantation 
Cystinosis Leukocyte cystine levels, slit lamp 
exam of the eyes, genetic testing 
for the cystinosin gene 
Cysteamine substitution 
Coenzyme Q10-related 
gene mutations causing 
FSGS 
Genetic testing for AarF Domain 
Containing Kinase-4, coenzyme Q2, 
coenzyme Q6, and decaprenyl 
diphosphate synthase subunit 2 
Coenzyme Q10 replacement 
therapy 
C3 glomerulonephritis Kidney biopsy, specific 
complement test, genetic testing 
for complement-related genes 
Plasma exchange or blood 
transfusion, rituximab, eculizumab 
(depending on specific cause) 
Immune injury   
Acute or subacute immune 
complex 
glomerulonephritis 
Autoantibodies against nuclear 
autoantigens or neutrophil 
cytoplasmic antigens such as 
proteinase 3 or myeloperoxidase, 
Immunosuppressive drugs, plasma 




 C3/C4 serum levels urinary 
sediment, kidney biopsy 
 
Renal vasculitis ANCAs, urinary sediment, kidney 
biopsy 
Immunosuppressive drugs, plasma 
exchange (in certain settings) 
Vascular injury   
Recent onset renal artery 
stenosis (fibromuscular or 
vasculitic) 
Angiogram of the renal arteries Surgical revascularization or 
catheter-based angioplasty 
Metabolic injury   
Diabetic kidney disease Blood glucose level, albuminuria, 
kidney biopsy 
Antidiabetic drugs, SGLT2 
blockade, RAS inhibitors 
Chronic urate nephropathy Tophaceous gout, serum uric acid 
levels, kidney biopsy 
Purine-reduced diet, uricosuric 
drugs, xanthine oxidase inhibitors, 
rasburicase 
Toxic injury   
Toxic nephropathies (lead, 
aristolochic acid, 
phenacetin, …) 
History, specific toxin levels, kidney 
biopsy 
Abandon toxin exposure 
Multiple myeloma Serum or urinary free light chain 
test, bone marrow aspirate, kidney 
biopsy 
Myeloma-directed chemotherapy 
Kidney infections   
Bacterial pyelonephritis Urine culture Increased fluid intake, antibiotics 
Viral nephropathies Viral testing, kidney biopsy Antiviral therapy 
Mechanical injury   
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